Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

Abstract:

:Elevated circulating chromogranin A (CgA) levels are found in neuroendocrine tumors (NETs), but the diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian multicenter observational study has been performed. CgA was evaluated in 202 GEP NET patients by IRMA and ELISA. The cutoffs for diagnosis and presence of metastases were identified by receiver-operating characteristic (ROC) curve. We found good correlation between IRMA and ELISA. The ROC analysis identified a cutoff of 53 ng/ml for IRMA and 16 U/l for ELISA as discriminating between controls and patients with active disease (sensitivity 71.3 and 84%; specificity 71 and 85% respectively). Metastases were present in 123 patients, having significantly higher CgA levels than patients without metastases. ROC analysis identified a cutoff of 146 ng/ml for IRMA and 67.3 U/l for ELISA as discriminating between patients with and without metastases (sensitivity 57 and 63.3%; specificity 55.6 and 71.4% respectively). For pancreatic NETs positive and negative predictive values were 84 and 78% respectively (90% specificity and 68% sensitivity). We found lower CgA levels in patients with extensive metastatic spread than in those with liver metastases only. These data assess the role of CgA evaluation in GEP NETs, and demonstrate that higher CgA levels associate with metastatic disease, confirming that CgA levels can provide a helpful practical biochemical marker for the clinical management of NETs, but with low sensitivity and specificity.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Zatelli MC,Torta M,Leon A,Ambrosio MR,Gion M,Tomassetti P,De Braud F,Delle Fave G,Dogliotti L,degli Uberti EC,Italian CromaNet Working Group.

doi

10.1677/ERC-07-0001

subject

Has Abstract

pub_date

2007-06-01 00:00:00

pages

473-82

issue

2

eissn

1351-0088

issn

1479-6821

pii

14/2/473

journal_volume

14

pub_type

杂志文章,多中心研究
  • FOXO factors and breast cancer: outfoxing endocrine resistance.

    abstract::The majority of metastatic breast cancers cannot be cured and present a major public health problem worldwide. Approximately 70% of breast cancers express the estrogen receptor, and endocrine-based therapies have significantly improved patient outcomes. However, the development of endocrine resistance is extremely com...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0461

    authors: Bullock M

    更新日期:2016-02-01 00:00:00

  • Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.

    abstract::The function of estrogen receptor beta (ER-beta) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene. A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01088

    authors: Rody A,Holtrich U,Solbach C,Kourtis K,von Minckwitz G,Engels K,Kissler S,Gätje R,Karn T,Kaufmann M

    更新日期:2005-12-01 00:00:00

  • Hormone receptor status does not alter the effect of trastuzumab in breast cancer.

    abstract::Overexpression of human epidermal growth factor receptor 2 (HER2) predicts response to anti-HER2 therapy in breast cancer. We investigated whether hormone receptor (HR) status influences the treatment benefit of trastuzumab in patients with breast cancer. Data from 8338 patients with primary nonmetastatic breast cance...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0084

    authors: Ignatov T,Eggemann H,Burger E,Costa SD,Ignatov A

    更新日期:2016-05-01 00:00:00

  • FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.

    abstract::Ovarian epithelial cancer is the leading cause of death among gynecological malignancies. FSH may increase the risk of ovarian malignancy and play an important role in ovarian carcinogenesis. Our previous studies showed that FSH increases the expression of VEGF through survivin. In this study, the function and mechani...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0308

    authors: Huang Y,Jin H,Liu Y,Zhou J,Ding J,Cheng KW,Yu Y,Feng Y

    更新日期:2010-11-30 00:00:00

  • Role of biomarkers in predicting the occurrence of thyroid neoplasms in radiation-exposed children.

    abstract::With increasing numbers of childhood cancer survivors who were treated with radiation, there is a need to evaluate potential biomarkers that could signal an increased risk of developing thyroid cancer. We aimed to examine the relationships between thyrotropin and thyroglobulin levels and the risk of developing thyroid...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0408

    authors: Shulan JM,Vydro L,Schneider AB,Mihailescu DV

    更新日期:2018-04-01 00:00:00

  • Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation.

    abstract::Obestatin was identified as a gut peptide encoded by the ghrelin gene that interacts with the G protein-coupled receptor, GPR39. In this work, a sequential analysis of its transmembrane signalling pathway has been undertaken to characterize the intracellular mechanisms responsible for Akt activation. The results show ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0192

    authors: Alvarez CJ,Lodeiro M,Theodoropoulou M,Camiña JP,Casanueva FF,Pazos Y

    更新日期:2009-06-01 00:00:00

  • Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.

    abstract::Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer....

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0078

    authors: Yamashita H,Nishio M,Toyama T,Sugiura H,Kondo N,Kobayashi S,Fujii Y,Iwase H

    更新日期:2008-09-01 00:00:00

  • HES5 silencing is an early and recurrent change in prostate tumourigenesis.

    abstract::Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation prof...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0454

    authors: Massie CE,Spiteri I,Ross-Adams H,Luxton H,Kay J,Whitaker HC,Dunning MJ,Lamb AD,Ramos-Montoya A,Brewer DS,Cooper CS,Eeles R,UK Prostate ICGC Group.,Warren AY,Tavaré S,Neal DE,Lynch AG

    更新日期:2015-04-01 00:00:00

  • New drugs for medullary thyroid cancer: new promises?

    abstract::Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized M...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0104

    authors: Spitzweg C,Morris JC,Bible KC

    更新日期:2016-06-01 00:00:00

  • Apoptosis in breast cancer: relationship with other pathological parameters.

    abstract::Apoptosis is a frequent phenomenon in breast cancer and it can be detected by light microscopy in conventional histopathological sections or by special staining techniques. The number of apoptotic cells as a percentage of cells present, or the number of apoptotic cells per square millimetre of neoplastic tissue, is us...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060013

    authors: Lipponen P

    更新日期:1999-03-01 00:00:00

  • Endocrine complications in long-term survivors of childhood cancers.

    abstract::Endocrine disturbances are among the most frequently reported complications in childhood cancer survivors, affecting between 20 and 50% of individuals who survive into adulthood. Most endocrine complications are the result of prior cancer treatments, especially radiotherapy. The objective of the present review is to d...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-10-0002

    authors: Chemaitilly W,Sklar CA

    更新日期:2010-06-03 00:00:00

  • Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.

    abstract::Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options. We explored novel treatment modalities by targeting epigenetic modifications using inhibitors of BET (e.g. BRD4) activity. We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0107

    authors: Zhu X,Park S,Lee WK,Cheng SY

    更新日期:2019-09-01 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs.

    abstract::The 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) held in Houston, TX, USA, focused on emerging topics in the pathogenesis and therapy of malignant endocrine tumors associated with MEN syndromes. With MEN-2 syndromes, the most common malignancy is medullary thyroid carcinoma (MTC). In the spirit o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0110

    authors: Dadu R,Bagheri-Yarmand R,Ringel MD,Grubbs EG,Zafereo M,Cote G,Gagel RF,Robinson BG,Shaw KR,Hu MI

    更新日期:2020-08-01 00:00:00

  • The LRIG family: enigmatic regulators of growth factor receptor signaling.

    abstract::The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins contains three vertebrate members (LRIG1, LRIG2 and LRIG3) and one member each in flies (Lambik) and worms (Sma-10). LRIGs have stepped into the spotlight as essential regulators of growth factor receptors, including recep...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-14-0179

    authors: Simion C,Cedano-Prieto ME,Sweeney C

    更新日期:2014-01-01 00:00:00

  • Acquired resistance to aromatase inhibitors: where we stand!

    abstract::Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen biosynthesis through aromatase inhibition, thus preventing tumour progression. Besides the therapeutic success of the third-generation AIs, acquired...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0425

    authors: Augusto TV,Correia-da-Silva G,Rodrigues CMP,Teixeira N,Amaral C

    更新日期:2018-05-01 00:00:00

  • Perspectives for immunotherapy in endocrine cancer.

    abstract::The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolut...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0169

    authors: Latteyer S,Tiedje V,Schilling B,Führer D

    更新日期:2016-10-01 00:00:00

  • microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.

    abstract::Na(+)/I(-) symporter (NIS)-mediated radioiodide uptake (RAIU) serves as the basis for targeted ablation of thyroid cancer remnants. However, many patients with thyroid cancer have reduced NIS expression/function and hence do not benefit from radioiodine therapy. microRNA (miR) has emerged as a promising therapeutic ta...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0439

    authors: Lakshmanan A,Wojcicka A,Kotlarek M,Zhang X,Jazdzewski K,Jhiang SM

    更新日期:2015-02-01 00:00:00

  • Rationale for the development of alternative forms of androgen deprivation therapy.

    abstract::With few exceptions, the almost 30,000 prostate cancer deaths annually in the United States are due to failure of androgen deprivation therapy. Androgen deprivation therapy prevents ligand-activation of the androgen receptor. Despite initial remission after androgen deprivation therapy, prostate cancer almost invariab...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0121

    authors: Kumari S,Senapati D,Heemers HV

    更新日期:2017-08-01 00:00:00

  • MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

    abstract::The high degree of conservation in microRNA from Caenorhabditiselegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microR...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0525

    authors: Smith B,Agarwal P,Bhowmick NA

    更新日期:2017-05-01 00:00:00

  • Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

    abstract::The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcr...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0017

    authors: Shiota M,Takeuchi A,Song Y,Yokomizo A,Kashiwagi E,Uchiumi T,Kuroiwa K,Tatsugami K,Fujimoto N,Oda Y,Naito S

    更新日期:2011-07-11 00:00:00

  • Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.

    abstract::Autotaxin is a secreted enzyme that converts extracellular lysophosphatidylcholine to lysophosphatidate (LPA). In cancers, LPA increases tumour growth, metastasis and chemoresistance by activating six G-protein coupled receptors. We examined >200 human thyroid biopsies. Autotaxin expression in metastatic deposits and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-15-0045

    authors: Benesch MG,Ko YM,Tang X,Dewald J,Lopez-Campistrous A,Zhao YY,Lai R,Curtis JM,Brindley DN,McMullen TP

    更新日期:2015-08-01 00:00:00

  • In vitro model systems to study androgen receptor signaling in prostate cancer.

    abstract::Prostate cancer (PCa) is one of the most common causes of male cancer-related death in Western nations. The cellular response to androgens is mediated via the androgen receptor (AR), a ligand-inducible transcription factor whose dysregulation plays a key role during PCa development and progression following androgen d...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0401

    authors: Sampson N,Neuwirt H,Puhr M,Klocker H,Eder IE

    更新日期:2013-03-26 00:00:00

  • Pituitary tumors contain a side population with tumor stem cell-associated characteristics.

    abstract::Pituitary adenomas cause significant endocrine and mass-related morbidity. Little is known about the mechanisms that underlie pituitary tumor pathogenesis. In the present study, we searched for a side population (SP) in pituitary tumors representing cells with high efflux capacity and potentially enriched for tumor st...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0546

    authors: Mertens F,Gremeaux L,Chen J,Fu Q,Willems C,Roose H,Govaere O,Roskams T,Cristina C,Becú-Villalobos D,Jorissen M,Poorten VV,Bex M,van Loon J,Vankelecom H

    更新日期:2015-08-01 00:00:00

  • Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.

    abstract::We report the case of an 8-year-old child who presented with severe hyperinsulinaemic hypoglycaemia due to a pancreatic islet cell adenoma. In vivo, there was no beneficial response to the hyperglycaemia-inducing agent diazoxide and as a consequence the child underwent a subtotal pancreatectomy. In vitro studies of ad...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0090221

    authors: Hussain K,Cosgrove KE,Shepherd RM,Chapman JC,Swift SM,Smith VV,Kassem SA,Glaser B,Lindley KJ,Aynsley-Green A,Dunne MJ

    更新日期:2002-12-01 00:00:00

  • Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

    abstract::There are currently few successful therapies for castration-resistant prostate cancer (CRPC). CRPC is thought to result from augmented activation of the androgen/androgen receptor (AR) signaling pathway, which could be enhanced by AR cofactors. In this study, heterochromatin protein 1beta (HP1beta), but not HP1alpha o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0321

    authors: Shiota M,Song Y,Yokomizo A,Tada Y,Kuroiwa K,Eto M,Oda Y,Inokuchi J,Uchiumi T,Fujimoto N,Seki N,Naito S

    更新日期:2010-05-18 00:00:00

  • Molecular signatures of thyroid follicular neoplasia.

    abstract::The molecular pathways leading to thyroid follicular neoplasia are incompletely understood, and the diagnosis of follicular tumors is a clinical challenge. To provide leads to the pathogenesis and diagnosis of the tumors, we examined the global transcriptome signatures of follicular thyroid carcinoma (FC) and normofol...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0288

    authors: Borup R,Rossing M,Henao R,Yamamoto Y,Krogdahl A,Godballe C,Winther O,Kiss K,Christensen L,Høgdall E,Bennedbaek F,Nielsen FC

    更新日期:2010-07-28 00:00:00

  • Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.

    abstract::Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deleti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0002

    authors: Hammoud Z,Tan B,Badve S,Bigsby RM

    更新日期:2008-06-01 00:00:00

  • Peroxisome proliferator-activated receptor gamma and BRCA1.

    abstract::Peroxisome proliferator-activated receptor gamma agonists have been proposed as breast cancer preventives. Individuals who carry a mutated copy of BRCA1, DNA repair-associated gene, are at increased risk for development of breast cancer. Published data in the field suggest there could be interactions between peroxisom...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0449

    authors: Furth PA

    更新日期:2019-02-01 00:00:00

  • BRAF mutation in thyroid cancer.

    abstract::Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon which novel approaches to the management of thyroid cancer can be developed. A recent important genetic finding in thyroid cancer is the oncogenic T1799A transversion mutation of BRAF (the gene for the B-type Raf kinase, BRAF...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.0978

    authors: Xing M

    更新日期:2005-06-01 00:00:00

  • Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

    abstract::Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized. In this study, using smal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0285

    authors: Karmakar S,Foster EA,Blackmore JK,Smith CL

    更新日期:2010-12-21 00:00:00